Summary
This study is testing a new experimental targeted treatment called IMP1734 (also known as EIK1003) in people with advanced cancers that have spread or come back after treatment.
The main aims of the study are to:
- Find out how safe the drug is and what side effects it may cause
- Determine the best dose to use in future studies
- Learn how the body absorbs, processes and responds to the drug
- Look for early signs that IMP1734 may help control cancer.
Who can take part?
You may be eligible for this study if:
- you are aged 18 years or older
- you have one of the following cancers:
- breast cancer, and have received at least one prior chemotherapy treatment. If your cancer is HR+ you also need to have had hormone therapy
- ovarian cancer (including high-grade serous and high-grade endometrioid ovarian cancer), fallopian tube cancer, or primary peritoneal cancer, and have received at least one platinum-based chemotherapy for advanced disease
- metastatic castration-resistant prostate cancer (mCRPC), and are receiving ADT and have previously received a new hormonal agent and up to one prior taxane chemotherapy
- your cancer has come back, spread, or continued to grow after previous treatment
- your cancer has a mutation in an HRR gene
The study has two parts.
Part 1
Researchers will gradually increase the dose of IMP1734 to find the highest dose that can be given safely.
Part 2
Researchers will test and compare selected dose levels to determine the most appropriate dose for future clinical development.
Participants will receive IMP1734 on its own during the study.
Conditions
This trial is treating people with advanced breast, ovarian, fallopian tube, primary peritoneal or prostate cancer.